GlassScriptPhysician profile
Chikara Gothong
NPI 1982125225
$3,824.02
in general payments reported to CMS, 2019-2025
23 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $592 · 2023: $809 · 2024: $1,476 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.39 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $857.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $407.80 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Corcept Therapeutics | $308.19 | 2023-2025 | Korlym |
| Tandem Diabetes Care, INC. | $266.90 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $259.33 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $222.49 | 2024-2025 | Recorlev |
| Sanofi-Aventis U.S. LLC | $208.30 | 2022-2025 | |
| Insulet Corporation | $191.36 | 2022-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $154.52 | 2023-2024 | Farxiga |
| Amneal Pharmaceuticals LLC | $151.19 | 2024-2025 | Unithroid |
| Medtronic, INC. | $139.37 | 2022-2023 | Minimed 770g, Minimed 780g |
| Abbvie INC. | $119.32 | 2022-2025 | |
| Cequr Corporation | $102.58 | 2024-2025 | Cequr Simplicity |
| Abbott Laboratories | $82.26 | 2023-2024 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $67.97 | 2025 | Twiist |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $64.21 | 2024-2025 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $62.70 | 2025 | Gardasil 9, Capvaxive, M-M-R II |
| Astellas Pharma US INC | $46.81 | 2024-2025 | Veozah |
| Amgen INC. | $36.09 | 2024-2025 | Krystexxa, Repatha |
| Amryt Pharma Holdings LTD | $23.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2025 | Jardiance |
| Sanofi Pasteur INC. | $16.80 | 2023 | |
| Acella Pharmaceuticals, LLC | $14.52 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chikara Gothong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.